Interferon-&alpha; plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B

doi:10.3748/wjg.v11.i37.5882

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 37

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2835)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-6) series, Tables (1-1) series.

Item

Count

PDF

242

HTML

2125

Figures (1-6)

253

Tables (1-1)

215

Sum=2835

Oct 7, 2005 (publication date) through Dec 22, 2024

Times Cited of This Article

Times Cited (19)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Reports

World J Gastroenterol. Oct 7, 2005; 11(37): 5882-5887
Published online Oct 7, 2005. doi: 10.3748/wjg.v11.i37.5882

Full Size Figure Download Figure

Figure 3 Combination treatment delayed the VBR compared to lamivudine monotherapy among patients who had lowered their HBV DNA concentrations below detection. IFN: Interferon-α.

Citation: Economou M, Manolakopoulos S, Trikalinos TA, Filis S, Bethanis S, Tzourmakliotis D, Avgerinos A, Raptis S, Tsianos EV. Interferon-α plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. World J Gastroenterol 2005; 11(37): 5882-5887
URL: https://www.wjgnet.com/1007-9327/full/v11/i37/5882.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i37.5882